| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,950 | 4,250 | 17:11 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.11. | SMAIO Has Reappointed Dr Tenner Guillaume to Its Scientific Advisory Board in the United States | 340 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics Euronext Growth Paris, ISIN code: FR0014005I80 Ticker: ALSMA, PEA-PME eligible), a French-American company specialized... ► Artikel lesen | |
| 13.10. | SMAIO Reports First-Half 2026 Results and Sales for the Third Quarter of 2026 | 558 | Business Wire | Half-year sales rose by 3% to €5.1m, driven by implant sales in the United States, which increased by 3% to €3.9m (up 10% to $4.5m, excluding currency effects)
Solid gross margin of 81%... ► Artikel lesen | |
| 06.10. | SMAIO Signs a New Collaboration for its KEOPS-4ME Open Platform in the United States | 478 | Business Wire | This new agreement marks the acceleration of SMAIO's collaborative strategy aimed at rolling out its open platform for customized implant solutions in the US market.
Regulatory News:
SMAIO... ► Artikel lesen | |
| 03.09. | SMAIO has Reappointed Dr Donald J. Blaskiewicz to its Scientific Advisory Board in the United States | 509 | Business Wire | Regulatory news:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics Euronext Growth Paris, ISIN code: FR0014005I80 Ticker: ALSMA, PEA-PME eligible), a French-American company specialized... ► Artikel lesen | |
| 16.07. | SMAIO Reports Sales for the First Half of 2026 | 516 | Business Wire | Up 3% to €5.1m, first-half sales exceeded the €5m mark for the first time, despite four months of temporary absence of one of the top-performing surgeons in the United States
U.S. sales... ► Artikel lesen | |
| 12.05. | SMAIO Reported Revenue of €2.8 Million in the First Quarter of 2026, an Increase of 11% | 528 | Business Wire | Revenue in the United States reached a record quarterly high of €2.3 million (+21%), or $2.6 million (+35%)1 excluding currency effects
The United States accounts for nearly 80% of the... ► Artikel lesen | |
| S.M.A.I.O SA Aktie jetzt für 0€ handeln | |||||
| 11.05. | SMAIO Expands Its North American Scientific Advisory Board With a New Renowned Surgeon | 456 | Business Wire | Appointment of Dr. Jeffrey M. Hills, an orthopedic surgeon specializing in complex spinal conditions SMAIO's Scientific Advisory Board, now comprised of five members, is a key asset in... ► Artikel lesen | |
| 05.05. | SMAIO Announces that Portzamparc (BNP Paribas Group) has Initiated Coverage of its Stock with a Buy Rating | 607 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptive Implants in Orthopaedics Euronext Growth Paris, ISIN Code: FR0014005I80 Ticker: ALSMA), a French-American company specialized in complex... ► Artikel lesen | |
| 06.03. | SMAIO Announces a €3.6 Million Capital Increase to Support Its Long-Term Growth Momentum | 745 | Business Wire | Capital increase totaling €3.6 million gross through the issuance of shares with stock warrants (ABSAs) at a price of €7 per share
4 warrants will entitle the holder to subscribe for one... ► Artikel lesen | |
| 20.01. | SMAIO Reports 2025 Sales of €9.2m, Representing an Increase of +67% | 558 | Business Wire | U.S. sales rose by +138% to €7m, and by +160% to $7.9m (excluding currency effects).
Strong growth across North American centers that were already active in 2024 (+130%). 11 new... ► Artikel lesen | |
| 08.01. | SMAIO: 2026 Financial Calendar | 676 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptive Implants in Orthopaedics Euronext Growth Paris, ISIN: FR0014005I80 Ticker: ALSMA), a French-American player specialized in complex spine... ► Artikel lesen | |
| 06.01. | SMAIO Obtains €2.0m in Non-Dilutive Financing | 615 | Business Wire | €1.0m in the form of a 0% interest loan co-financed by the European Union, the Auvergne-Rhône-Alpes Region and Bpifrance, with a repayment deferral period of two and a half years €1.0m... ► Artikel lesen | |
| 19.12.25 | SMAIO Successfully Continues Its Think Tanks Focused on Promoting Its Innovative Solutions in the United States | 971 | Business Wire | New attendance record at the New York session, bringing together nearly 60 experts from the spine sector, including over 40 surgeons
Regulatory News:
SMAIO (Software, Machines and Adaptative... ► Artikel lesen | |
| 24.11.25 | SMAIO Appoints Matthieu Ville as Chief Commercial Officer to Accelerate Commercialization and Strengthen Its Leadership in Spinal Realignment | 513 | Business Wire | Matthieu Ville brings over 15 years of experience in medical marketing in the United States.
Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics- Euronext Growth... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 51,55 | -0,44 % | Fresenius-Chef fordert grundlegende Gesundheitsreform | Berlin - Der Chef des Gesundheitskonzerns Fresenius, Michael Sen, fordert eine grundlegende Reform des deutschen Gesundheitssystems. Wenn Deutschland nicht handle, habe das System das Potenzial, "dass... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,760 | +2,83 % | BERENBERG stuft FMC FRESENIUS MEDICAL CARE AG auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für FMC nach Zahlen zum dritten Quartal von 42 auf 37 Euro gesenkt, die Einstufung aber auf "Hold" belassen. Das bereinigte operative... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,230 | -1,35 % | Siemens Healthineers Aktie: Zwischen Übergangsjahr und Kursfantasie | Die Analysten sind sich nach den jüngsten Quartalszahlen von Siemens Healthineers uneinig über die weiteren Perspektiven der Aktie. Während Jefferies nach der Erholung im Geschäft mit medizinischer... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 63,56 | -0,67 % | BMO raises BrightSpring Health stock price target on LDD momentum | ||
| HEARTFLOW | 45,730 | +2,42 % | Heartflow stock tumbles despite strong growth beating Q3 expectations | ||
| LIFESTANCE HEALTH GROUP | 13,630 | +2,17 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 25,300 | +2,47 % | Privia Health Group, Inc.: Privia Health Reports Strong Results in the 2025 Performance Year of the Medicare Shared Savings Program | ||
| GERRESHEIMER | 32,060 | -2,85 % | Gerresheimer: Was Anleger vor dem Jahresfinale prüfen sollten | ||
| PROGYNY | 35,860 | +1,16 % | Rekorde bei Familienplanung: Progyny glänzt mit blitzsauberer Bilanz und massiven Rückkäufen | Hier an der Wall Street in New York wird oft das schnelle Geld gesucht. Doch die wahren Börsenperlen findet man häufig in lukrativen Nischen, in denen ein Unternehmen zum unverzichtbaren Marktführer... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 25,860 | +0,43 % | Procept BioRobotics outlines $390M-$410M 2026 revenue, while targeting positive adjusted EBITDA in Q4 | ||
| ALIGNMENT HEALTHCARE | 6,565 | +1,00 % | Alignment Healthcare falls 9% amid weakness in Medicare Advantage stocks | ||
| UNITEDHEALTH | 314,80 | +4,58 % | UnitedHealth-Aktie -15%: Washington zieht die Daumenschrauben an - trotzdem kaufen? | Es ist bislang eine rabenschwarze Woche für die UnitedHealth-Aktie. Am Dienstag und am Mittwoch brach der Kurs der größten privaten US-Krankenversicherung in Summe um -15% ein. Was steckt hinter dem... ► Artikel lesen | |
| DRAEGERWERK | 117,20 | +1,21 % | Drägerwerk Vz.: Darf man diesem Braten trauen? | Im Rahmen des am Mittwoch abgehaltenen Kapitalmarkttages stellte der Medizin- und Sicherheitstechnik-Spezialist Drägerwerk seine Ziele bis zum Jahr 2030 vor. Die Anleger quittierten das mit Käufen,... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,060 | -0,62 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 27 auf 26 Euro gekappt und die Aktien von "Equal Weight" auf "Underweight" abgestuft. Dem... ► Artikel lesen | |
| GENEDX | 47,130 | -4,29 % | GeneDx Taps Everett Cunningham as CEO |